Results 81 to 90 of about 16,727 (107)
Some of the next articles are maybe not open access.

Effectiveness of Two New Endochin-like Quinolones, ELQ-596 and ELQ-650, in Experimental Mouse Models of Human Babesiosis

ACS Infectious Diseases
Endochin-like quinolones (ELQs) define a class of small molecule antimicrobials that target the mitochondrial electron transport chain of various human parasites by inhibiting their cytochrome bc1 complexes.
Pratap Vydyam   +2 more
exaly   +2 more sources

KU-596 decreases mitochondrial superoxide and improves bioenergetics following downregulation of manganese superoxide dismutase in diabetic sensory neurons

open access: yesExperimental Neurology, 2019
Neuronal mitochondrial dysfunction and oxidative stress are key pathophysiologic mechanisms of diabetic peripheral neuropathy (DPN). KU‐596 is a small molecule modulator of heat shock protein 90 (Hsp90) that can reverse clinically relevant measures of ...
Brian S J Blagg, Rick T Dobrowsky
exaly   +2 more sources

Long-Term Complications of Cranioplasty Using Stored Autologous Bone Graft, Three-Dimensional Polymethyl Methacrylate, or Titanium Mesh After Decompressive Craniectomy: A Single-Center Experience After 596 Procedures.

World Neurosurgery, 2019
OBJECTIVE Cranioplasty is a technically simple procedure intended to repair defects of the skull to provide protection after craniectomy, improve functional outcomes, and restore cosmesis.
Mun-Chun Yeap   +11 more
semanticscholar   +1 more source

RHPN1-AS1 drives the progression of hepatocellular carcinoma via regulating miR-596/IGF2BP2 axis.

Current pharmaceutical design, 2019
BACKGROUND Hepatocellular carcinoma (HCC) is one of the most deadly cancer worldwide, and its incidence is especially in China. Multiple long non-coding RNAs (lncRNAs) have been recently identified as crucial oncogenic factors or tumor suppressors.
Hu Fen   +6 more
semanticscholar   +1 more source

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

open access: yesAnnals of Oncology, 2015
C. Cremolini   +18 more
exaly   +2 more sources

Novel anti-EGFRvIII bispecific T cell engager (BiTE) antibody construct in glioblastoma (GBM): Trial in progress of AMG 596 in patients with recurrent or newly diagnosed disease.

Journal of Clinical Oncology, 2019
TPS2071 Background: GBM is the most aggressive primary brain tumor in adults and is extremely difficult to treat. Patients with GBM tend to progress rapidly within weeks or months. Median overall survival is only 12–15 months despite aggressive treatment,
M. Rosenthal   +10 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy